ZA201806849B - Acetyl¿leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function - Google Patents
Acetyl¿leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive functionInfo
- Publication number
- ZA201806849B ZA201806849B ZA2018/06849A ZA201806849A ZA201806849B ZA 201806849 B ZA201806849 B ZA 201806849B ZA 2018/06849 A ZA2018/06849 A ZA 2018/06849A ZA 201806849 A ZA201806849 A ZA 201806849A ZA 201806849 B ZA201806849 B ZA 201806849B
- Authority
- ZA
- South Africa
- Prior art keywords
- leucine
- acetyl
- pharmaceutically acceptable
- acceptable salt
- cognitive function
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606834 | 2016-04-19 | ||
| PCT/GB2017/051090 WO2017182802A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201806849B true ZA201806849B (en) | 2019-07-31 |
Family
ID=58633040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/06849A ZA201806849B (en) | 2016-04-19 | 2018-10-15 | Acetyl¿leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10905670B2 (https=) |
| EP (2) | EP4501406A3 (https=) |
| JP (3) | JP7387264B2 (https=) |
| KR (4) | KR102791288B1 (https=) |
| CN (2) | CN109069463B (https=) |
| AU (2) | AU2017252507B2 (https=) |
| BR (1) | BR112018071547A2 (https=) |
| CA (1) | CA3021155A1 (https=) |
| DK (1) | DK3445351T3 (https=) |
| ES (1) | ES2994242T3 (https=) |
| FI (1) | FI3445351T3 (https=) |
| HR (1) | HRP20241552T1 (https=) |
| HU (1) | HUE069219T2 (https=) |
| IL (3) | IL310508A (https=) |
| LT (1) | LT3445351T (https=) |
| MD (1) | MD3445351T2 (https=) |
| MX (2) | MX388461B (https=) |
| PL (1) | PL3445351T3 (https=) |
| PT (1) | PT3445351T (https=) |
| RS (1) | RS66142B1 (https=) |
| RU (1) | RU2745912C2 (https=) |
| SG (2) | SG10202106190RA (https=) |
| SI (1) | SI3445351T1 (https=) |
| SM (1) | SMT202400459T1 (https=) |
| WO (1) | WO2017182802A1 (https=) |
| ZA (1) | ZA201806849B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10905670B2 (en) * | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| WO2018029658A1 (en) | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| JP7471298B2 (ja) | 2018-12-06 | 2024-04-19 | イントラビオ エルティーディー | アセチル－ロイシンの重水素化類似体 |
| WO2020178721A1 (en) * | 2019-03-02 | 2020-09-10 | Intrabio Ltd. | Leucine, acetyl leucine, and related analogs for treating disease |
| US20250099355A1 (en) | 2023-07-18 | 2025-03-27 | Sytheon Ltd | Amino acid based salts, compositions and methods for treating skin and improving skin rejuvenation and longevity |
| WO2025166100A1 (en) | 2024-02-02 | 2025-08-07 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| US20080097606A1 (en) * | 2006-10-19 | 2008-04-24 | Cragg Andrew H | Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis |
| CA2687107A1 (en) * | 2007-05-08 | 2008-11-13 | Northern Innovations And Formulations Corp. | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
| US20120196257A1 (en) * | 2009-08-27 | 2012-08-02 | Joe Verghese | Cognitive function training to improve motor ability |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| US10905670B2 (en) * | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| US12458614B2 (en) * | 2017-10-18 | 2025-11-04 | Intrabio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
-
2017
- 2017-04-19 US US16/093,780 patent/US10905670B2/en active Active
- 2017-04-19 KR KR1020247003393A patent/KR102791288B1/ko active Active
- 2017-04-19 MX MX2018012739A patent/MX388461B/es unknown
- 2017-04-19 HR HRP20241552TT patent/HRP20241552T1/hr unknown
- 2017-04-19 CA CA3021155A patent/CA3021155A1/en active Pending
- 2017-04-19 FI FIEP17719692.0T patent/FI3445351T3/fi active
- 2017-04-19 KR KR1020227008412A patent/KR102413754B1/ko active Active
- 2017-04-19 IL IL310508A patent/IL310508A/en unknown
- 2017-04-19 KR KR1020187032983A patent/KR20180134398A/ko not_active Ceased
- 2017-04-19 PT PT177196920T patent/PT3445351T/pt unknown
- 2017-04-19 CN CN201780029480.6A patent/CN109069463B/zh active Active
- 2017-04-19 PL PL17719692.0T patent/PL3445351T3/pl unknown
- 2017-04-19 EP EP24205813.9A patent/EP4501406A3/en active Pending
- 2017-04-19 IL IL293266A patent/IL293266B2/en unknown
- 2017-04-19 CN CN202410876111.2A patent/CN118593463A/zh active Pending
- 2017-04-19 KR KR1020227021015A patent/KR102632670B1/ko active Active
- 2017-04-19 EP EP17719692.0A patent/EP3445351B1/en active Active
- 2017-04-19 HU HUE17719692A patent/HUE069219T2/hu unknown
- 2017-04-19 LT LTEPPCT/GB2017/051090T patent/LT3445351T/lt unknown
- 2017-04-19 AU AU2017252507A patent/AU2017252507B2/en active Active
- 2017-04-19 RU RU2018140131A patent/RU2745912C2/ru active
- 2017-04-19 SM SM20240459T patent/SMT202400459T1/it unknown
- 2017-04-19 SG SG10202106190RA patent/SG10202106190RA/en unknown
- 2017-04-19 BR BR112018071547-6A patent/BR112018071547A2/pt not_active Application Discontinuation
- 2017-04-19 JP JP2018555644A patent/JP7387264B2/ja active Active
- 2017-04-19 SI SI201731566T patent/SI3445351T1/sl unknown
- 2017-04-19 IL IL262379A patent/IL262379B/en unknown
- 2017-04-19 ES ES17719692T patent/ES2994242T3/es active Active
- 2017-04-19 MD MDE20190248T patent/MD3445351T2/ro unknown
- 2017-04-19 RS RS20241222A patent/RS66142B1/sr unknown
- 2017-04-19 WO PCT/GB2017/051090 patent/WO2017182802A1/en not_active Ceased
- 2017-04-19 SG SG11201809031XA patent/SG11201809031XA/en unknown
- 2017-04-19 DK DK17719692.0T patent/DK3445351T3/da active
-
2018
- 2018-10-15 ZA ZA2018/06849A patent/ZA201806849B/en unknown
- 2018-10-18 MX MX2021014844A patent/MX2021014844A/es unknown
-
2020
- 2020-12-22 US US17/247,757 patent/US11998518B2/en active Active
-
2021
- 2021-11-12 JP JP2021185130A patent/JP7506046B2/ja active Active
-
2022
- 2022-10-17 AU AU2022256077A patent/AU2022256077A1/en not_active Abandoned
-
2023
- 2023-07-10 US US18/349,221 patent/US12329733B2/en active Active
-
2024
- 2024-06-13 JP JP2024096260A patent/JP2024123087A/ja active Pending
-
2025
- 2025-05-13 US US19/206,473 patent/US20250332133A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2572126B (en) | Pharmaceutical | |
| GB2569961B (en) | Pharmaceutical | |
| ZA201806849B (en) | Acetyl¿leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function | |
| GB2572125B (en) | Pharmaceutical | |
| SG11201609405VA (en) | Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof | |
| EP3638658C0 (en) | PHARMACEUTICAL COMPOUNDS | |
| SG11202012447YA (en) | Rapamycin analogs and uses thereof | |
| GB201704965D0 (en) | Pharmaceutical compounds | |
| GB201703881D0 (en) | Pharmaceutical compounds | |
| ZA201904241B (en) | Novel compound and pharmacologically acceptable salt thereof | |
| IL272385A (en) | Drug compound and methods of preparation | |
| SG11201705759SA (en) | Cytotoxic hexim1 peptides and uses thereof | |
| GB201706806D0 (en) | Pharmaceutical compounds | |
| IL267937A (en) | Amide compounds and their use | |
| IL276323A (en) | 4-Methyldihydropyrimidinone compounds and their pharmaceutical use | |
| GB201704966D0 (en) | Pharmaceutical compounds | |
| IL283273A (en) | Pharmacy practices | |
| PL3438118T3 (pl) | Pochodna peptydu i jej zastosowanie | |
| IL271741A (en) | Peptide meters drug with improved pharmaceutical properties | |
| GB201702051D0 (en) | New Pharmaceutical use | |
| GB201608175D0 (en) | A composition for the detection of a drug | |
| GB201700867D0 (en) | Pharmaceutical compounds |